Metabolic & Incretin

Incretin mimetics and metabolic modulators investigated in glucose homeostasis and adiposity literature.

AOD-9604

MW: 1817.1 g/mol
Half-life: Short (minutes, plasma)
Class: hGH(177-191) C-terminal fragment

Metabolic & Incretin

Cagrilintide

AM833

CAGRILINTIDE

MW: ≈ 3950 g/mol
Half-life: ≈ 7 days
Class: Long-acting amylin analogue

Metabolic & Incretin

Exenatide

Byetta · Bydureon · Exendin-4

EXENATIDE

MW: 4186.6 g/mol
Half-life: ≈ 2.4 h (immediate release)
Class: Exendin-4 GLP-1 receptor agonist

Metabolic & Incretin

Glucagon

GLUCAGON

MW: 3482.8 g/mol
Half-life: ≈ 3–6 min (IV)
Class: 29-amino-acid pancreatic peptide hormone

Metabolic & Incretin

Liraglutide

Victoza · Saxenda

LIRAGLUTIDE

MW: 3751.2 g/mol
Half-life: ≈ 13 h
Class: Acylated GLP-1 receptor agonist

Metabolic & Incretin

Mazdutide

IBI362 · LY3305677 · OXM analogue

MAZDUTIDE

MW: ≈ 4300 g/mol
Half-life: ≈ 5–6 days
Class: GLP-1 / glucagon (oxyntomodulin) dual agonist

Metabolic & Incretin

Pramlintide

Symlin · Amylin analogue

PRAMLINTIDE

MW: 3949.4 g/mol
Half-life: ≈ 48 min
Class: Synthetic amylin (IAPP) analogue

Metabolic & Incretin

Retatrutide

LY3437943 · GLP-1/GIP/Glucagon triple agonist

RETATRUTIDE

MW: ≈ 4900 g/mol
Half-life: ≈ 6 days
Class: Triple GLP-1 / GIP / Glucagon receptor agonist

Metabolic & Incretin

Semaglutide

SEMAGLUTIDE

MW: 4113.6 g/mol
Half-life: ≈ 165 h (≈ 1 week)
Class: GLP-1 receptor agonist (incretin mimetic)

Metabolic & Incretin

Survodutide

BI 456906

SURVODUTIDE

MW: ≈ 4500 g/mol
Half-life: ≈ 6 days
Class: Dual glucagon / GLP-1 receptor agonist

Metabolic & Incretin

Tirzepatide

TIRZEPATIDE

MW: 4813.5 g/mol
Half-life: ≈ 120 h (≈ 5 days)
Class: Dual GIP / GLP-1 receptor agonist

Metabolic & Incretin

Ultratrutide

Next-generation triple agonist

ULTRATRUTIDE

MW: ≈ 5000 g/mol (reported)
Half-life: Weekly-dosing pharmacokinetics (reported)
Class: Multi-receptor incretin agonist (investigational)